Abstract A published so-called phase 3 study regarding HIPEC in ovarian cancer raised multiple questions. This commentary focusses on the weakness of the publication and discusses this in detail.
- Ovarian cancer
- Hyperthermic intraperitoneal chemotherapy
- Study design
Statistics from Altmetric.com
The authors declare no conflicts of interest.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.